Apologies, but no results were found. Perhaps searching will help find a related post.
Chief Executive Officer
Andrew is a seasoned executive with over 30 years in the medical device industry in both the private and public sectors.
Prior to joining the Fogarty Institute, he was vice president and general manager of Medtronic’s (MDT:NYSE) Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was president and CEO. Prior to Twelve, he was president and CEO of Ardian Inc., the pioneer of renal denervation for hypertension, heart failure and other associated disorders, which was also acquired by Medtronic in 2011. Together these two acquisitions totaled $1.5B.
Andrew began his career with the Australian Therapeutic Goods Administration, progressed to large medtech companies in Telectronics Pacing Systems and Baxter Healthcare (BAX:NYSE), then onto the Silicon Valley startup space working with Radiant Medical, Ardian and Twelve.
He is currently vice chairman of The Foundry, the premier medical device incubator based in Menlo Park, California, and serves as a director on the boards of two venture-funded companies — Saluda Medical and Zenflow, Inc. (chairman of the board). He was also a director at nVision Medical that was recently acquired by Boston Scientific (BSX:NYSE).
He currently serves on the advisory boards of venture capital firms Longitude Capital, Arboretum Ventures and Qiming Ventures; and of the UCSF-Stanford Pediatric Device Consortium.
Andrew has received numerous awards and honors and is a frequent guest lecturer at Stanford University. He is passionate about healthcare and a champion of innovators and innovation in the medtech field. He holds a BS (biophysics) from the Swinburne Institute of Technology.